National Health Investors (NHI) has just put fresh numbers on the table, reporting third quarter 2026 results that show US$113.48 million in revenue and a sharp jump in net income and earnings per share. Despite stronger third quarter figures and new 2026 guidance, National Health Investors’ recent share price performance has been weak. The stock is down 9.82% over the past week and 16.01% year to date at US$64.55. However, the 3-year and 5-year total shareholder returns of 41.75% and 51.45%...
National Health Investors is rated 'Hold' as portfolio shifts and recent asset sales pressure near-term earnings and dividend growth. Click to read more on NHI.
National Health Investors trades at a discount after a perceived unfavorable lease resolution and SHOP segment underperformance. Read why NHI stock is a buy.
Tipranks Press Release.
National Health Investors (NHI) invested $107.7 million to acquire six properties across Kentucky, M
National Health Investors (NHI) is scheduled to present at the BofA NY Global Real Estate Conference 2026 on September 15 in New York, offering investors updated insight into its senior housing and medical property portfolio. Recent trading has been softer, with National Health Investors’ share price down about 8% over the past month and roughly 13% year to date. However, the 3 year and 5 year total shareholder returns of 54.57% and 63.22% show a much stronger longer term picture. Compare...
Detailed price information for National Health Investors (NHI-N) from The Globe and Mail including charting and trades.
National Health Investors (NHI) has an average rating of overweight and mean price target of $81.56,
National Health Investors (NHI) has an average rating of overweight and mean price target of $81.88,
This is the newest page. Registered accounts read further back.